Apoferritin as an ubiquitous nanocarrier with excellent shelf life

dc.contributor.authorDostálová, Simonacs
dc.contributor.authorVašíčková, Kateřinacs
dc.contributor.authorHynek, Davidcs
dc.contributor.authorKřížková, Soňacs
dc.contributor.authorRichtera, Lukášcs
dc.contributor.authorVaculovičová, Markétacs
dc.contributor.authorEckschlager, Tomášcs
dc.contributor.authorStiborová, Mariecs
dc.contributor.authorHeger, Zbyněkcs
dc.contributor.authorAdam, Vojtěchcs
dc.coverage.issue1cs
dc.coverage.volume12cs
dc.date.accessioned2020-08-04T11:04:07Z
dc.date.available2020-08-04T11:04:07Z
dc.date.issued2017-03-24cs
dc.description.abstractDue to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo’s ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20°C, 4°C, 20°C, and 37°C in dark, and 4°C and 20°C under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20°C formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4°C showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 M of Dox) still retained its ability to inhibit completely the growth of 1.5×104 LNCaP cells after 72 hours. ApoDox stored at 20°C and 37°C in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4°C), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients.en
dc.formattextcs
dc.format.extent2265-2278cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationInternational Journal of Nanomedicine. 2017, vol. 12, issue 1, p. 2265-2278.en
dc.identifier.doi10.2147/IJN.S130267cs
dc.identifier.issn1178-2013cs
dc.identifier.other134900cs
dc.identifier.urihttp://hdl.handle.net/11012/69377
dc.language.isoencs
dc.publisherDove Media Presscs
dc.relation.ispartofInternational Journal of Nanomedicinecs
dc.relation.urihttps://www.dovepress.com/apoferritin-as-an-ubiquitous-nanocarrier-with-excellent-shelf-life-peer-reviewed-article-IJNcs
dc.rightsCreative Commons Attribution-NonCommercial 3.0 Unportedcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/1178-2013/cs
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/cs
dc.subjectanticancer therapyen
dc.subjectdoxorubicin-loaded apoferritinen
dc.subjectencapsulationen
dc.subjectlong-term stabilityen
dc.subjectprotein nanocarriersen
dc.titleApoferritin as an ubiquitous nanocarrier with excellent shelf lifeen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-134900en
sync.item.dbtypeVAVen
sync.item.insts2021.11.22 12:54:48en
sync.item.modts2021.11.22 12:25:42en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
IJN130267apoferritinasaubiquitousnanocarrierwithexcellentshelf_032417 1.pdf
Size:
3 MB
Format:
Adobe Portable Document Format
Description:
IJN130267apoferritinasaubiquitousnanocarrierwithexcellentshelf_032417 1.pdf